Citation of this article:Xu X,Rui F,Ni W,Wu C,Shi J,Li J.A Novel Algorithm for Streamlining Diagnosis of Advanced Liver Fibrosis in CHB Patients with Concurrent Hepatic Steatosis.J Clin Transl Hepatol 2024;12(2):222–...Citation of this article:Xu X,Rui F,Ni W,Wu C,Shi J,Li J.A Novel Algorithm for Streamlining Diagnosis of Advanced Liver Fibrosis in CHB Patients with Concurrent Hepatic Steatosis.J Clin Transl Hepatol 2024;12(2):222–226.doi:10.14218/JCTH.2023.00362.Chronic hepatitis B(CHB)with concurrent hepatic steatosis(HS)is a growing challenge for public health globally.展开更多
Metabolic dysfunction-associated steatotic liver disease(MASLD),formerly known as non-alcoholic fatty liver disease(NAFLD),is increasingly prevalent in Asia,1 an area also endemic for chronic hepatitis B(CHB).Our prev...Metabolic dysfunction-associated steatotic liver disease(MASLD),formerly known as non-alcoholic fatty liver disease(NAFLD),is increasingly prevalent in Asia,1 an area also endemic for chronic hepatitis B(CHB).Our previous study showed that the coexistence of CHB and hepatic steatosis(HS)has reached 36.5%in Asia,2 with a similar figure observed globally.3 This coexistence may exacerbate the progression of hepatic fibrosis.展开更多
文摘Citation of this article:Xu X,Rui F,Ni W,Wu C,Shi J,Li J.A Novel Algorithm for Streamlining Diagnosis of Advanced Liver Fibrosis in CHB Patients with Concurrent Hepatic Steatosis.J Clin Transl Hepatol 2024;12(2):222–226.doi:10.14218/JCTH.2023.00362.Chronic hepatitis B(CHB)with concurrent hepatic steatosis(HS)is a growing challenge for public health globally.
基金supported by the National Natural Science Fund(No.82170609,81970545)the Natural Science Foundation of Shandong Province(Major Project)(No.ZR2020KH006)+2 种基金LX was supported by the Tianjin Key Medical Discipline(Specialty)Construction Project(TJYXZDXK-059B)the Tianjin Health Science and Technology Project key discipline special(TJWJ2022XK034)the research project of Chinese traditional medicine and Chinese traditional medicine combined with Western medicine of Tianjin Municipal Health and Family Planning Commission(2021022).
文摘Metabolic dysfunction-associated steatotic liver disease(MASLD),formerly known as non-alcoholic fatty liver disease(NAFLD),is increasingly prevalent in Asia,1 an area also endemic for chronic hepatitis B(CHB).Our previous study showed that the coexistence of CHB and hepatic steatosis(HS)has reached 36.5%in Asia,2 with a similar figure observed globally.3 This coexistence may exacerbate the progression of hepatic fibrosis.
